Ricky Williams And Wellness Experts Discuss Strategies For Cannabis Patient-Centric Care

Zinger Key Points
  • Leaders discuss balancing medical cannabis access amid adult-use growth, emphasizing patient education and market integrity.
  • The shared insights into protecting patient rights in a fragmented regulatory landscape with strategies for medical cannabis advocacy.

At the recent Benzinga Cannabis Capital Conference, industry leaders explored the intersection of medical cannabis access, patient loyalty and market challenges.

Addressing key issues such as regulatory hurdles, changes in the medical marijuana market and the importance of patient education, the panel provided insights into maintaining patient care and access in a competitive market.

Navigating Accessibility And Risks To Medical Marijuana

Christina Betancourt Johnson, CEO of The Forest by Standard Wellness Maryland, highlighted the challenges in preserving patient access amid the rise of adult-use cannabis. Her company, which also operates in states like Utah, Missouri and Ohio, emphasizes the need for active engagement with elected officials and regulators to advocate for patients, especially when transitions between medical and adult use take place.

"We build those relationships long before coming into the market," she said. To her, lawmakers aren’t normally familiar with cannabis, so education is of the essence. In those conversations, Johnson advocates for tax breaks for medical users, mandatory shelf space dedicated to patients and enhanced budtender education to prioritize quality care as states transition to adult-use markets.

The ‘Friction' Between Medical And Adult-Use Markets

Founder of Leafwell, Emily Fisher, noted that the adult-use market introduces a type of "friction" that complicates access for patients. Leafwell aims to educate potential patients and partners, ensuring that therapeutic users are continually informed and supported, but Fisher recognized there’s much to be done still in that matter.

As regulations shift and new consumers enter the market, she said, "a lot of them are looking for therapeutic uses but don't get a medical card." Fisher attributes this to barriers that make navigating medical and adult-use markets challenging. To address those barriers, her company provides the largest integrated treatment clinic in the field, working across multiple markets where both programs coexist.

Read Also: Legal Medical Cannabis Could Save US Healthcare $29B Annually, New Study Finds

The Importance Of Medical Integrity

Tim Pickett, CEO of Kindly MD KDLY, a company based in Utah that offers plant-based treatments, echoed concerns about the potential risks to the medical cannabis sector. He explained that while retailers push for higher volumes, focusing on adult-use sales may come at a cost. "The fear is delegitimizing cannabis as a medicine.”

This shift risks overlooking a larger base of therapeutic cannabis users who might benefit from cannabis for health reasons but perceive it as purely recreational. Pickett advised that investors consider the long-term implications of focusing on adult-use marijuana, underscoring the substantial consumer base for medical cannabis.

  • Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you’re serious about the business, you can’t afford to miss out.

Exploring Identity And Wellness

Ricky Williams, former NFL player and founder of Highsman, addressed the broader, often philosophical aspects of cannabis in health. Reflecting on his experience as a professional athlete, Williams highlighted how perspectives on health vary, especially in fields like sports. "My interaction with physicians is very different than for most people," making the point that every person has a particular relation to both health and physicians. Thus, he advocated for broader conversations on cannabis’s therapeutic uses, as many consumers are likely unaware of the plant's benefits beyond recreational purposes.

Building on that conversation Javier Hasse, managing director at Benzinga Cannabis, brought up a conceptual distinction that resonated with the panel: the difference between "medical cannabis" and "therapeutic cannabis," which encompasses a wider range of health benefits.

"Why would people choose to go through the adult-use market route when medical cannabis might be more affordable and accessible?" Hasse asked.

This question underscores a common barrier in the U.S. where concerns about medical marijuana registration impacting government benefits, like housing or employment rights, prevent many from fully engaging in the medical market.

Confusion might be to blame, the panelists agreed noting that ambiguity and disorientation around cannabis legalization across states only exacerbate access challenges.

"The fact that we are not scheduled properly, and all 50 states are doing their own things, makes it difficult for consumers to understand what registering for a card looks like for their jobs, housing, and community," said Betancourt Johnson.

The panel concluded that unified clarity from cannabis advocates and regulators would enhance patient rights, reduce confusion and ultimately bolster the wellness cannabis market, which still has much room to grow.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.